We suggest a far more pro-active, empowered approach: a remission maintenance plan that offers cancer survivors a personalized program to regain control of their health, restore vitality and protect against the cancer returning.
This supports the single point in time approach to remission as discussed above, which for some patients in some circumstances may even only need to be low disease activity [ 3].
Only one of 17 patients who were autografted in or approaching marker remission subsequently developed disease progression (event-free survival 82%, 95% confidence interval [CI] 55%to94%4%), whereas all four patients who had progressive disease at autografting subsequently developed further disease progression and died.
While there is some data showing that changes in PANSS scores are related to quality of life measures, determining the best approach towards quantifying remission will require that both psychopathology and function be taken into account.
As with the ACR/EULAR committee's approach to defining remission [ 1], we examined predictive validity, defining it based on good radiographic and functional (health assessment questionnaire, HAQ) outcomes.
Understanding these mechanisms may provide novel approaches for prolonging remission periods for patients with UC.
However, with this approach, long-term remissions are achieved only in a minority of patients, resulting in a median overall survival (OS) of 9 to 42 months.
Therefore, for example, normal CRP was reported as '<10' in many clinics and DAS28-CRP cannot be calculated for all patients; CRP values of 0 to 9.9 provide DAS28 results different from CRP = 10, especially on low DAS28 levels approaching criteria for remission.
One approach to bringing full remission of symptoms to patients resistant to antidepressants is augmentation of the antidepressant medication.
In secondary analyses, we sought to examine if DTI measures were associated with time to remission, an approach used by others [25].
